ERBB2 and breast carcinoma: Additionally, the NATALEE trial demonstrated that the addition of three years of ribociclib combined with an aromatase inhibitor (AI) significantly prolonged iDFS in patients with HR-positive, HER2-negative stage II or III early breast cancer [9].